Related Experiment Video

Updated: Aug 12, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C

Fumiaki Kimura1, Hisao Hayashi, Motoyoshi Yano

  • 1Department of Internal Medicine, Tamano-Municipal Hospital, Tamano City, Okayama, Japan. f-kimura@po1.oninet.ne.jp

Hepato-Gastroenterology
|April 9, 2005
PubMed

Insights

Combining phlebotomy with a low iron diet significantly improves liver enzyme levels in chronic hepatitis C patients. This combined approach enhances iron reduction therapy beyond phlebotomy alone.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Iron-induced oxidative stress is a key factor in chronic hepatitis C pathogenesis.
  • Phlebotomy and low-iron diets individually improve transaminase levels in patients.
  • The combined efficacy of these treatments requires further investigation.

Purpose of the Study:

  • To evaluate the cooperative effects of phlebotomy and a low iron diet in treating chronic hepatitis C.
  • To determine if a low iron diet enhances the efficacy of phlebotomy in iron reduction therapy.

Main Methods:

  • A pilot study involving 21 chronic hepatitis C patients.
  • Group A (10 patients): phlebotomy alone.
  • Group B (11 patients): phlebotomy combined with a low iron diet (≤8 mg/day).
  • Phlebotomy continued until serum ferritin reached 10 ng/mL in both groups.

Main Results:

  • Both groups showed significant improvement in serum alanine aminotransferase (ALT) levels.
  • Group B (low iron diet + phlebotomy) exhibited significantly lower post-treatment ALT levels compared to Group A (phlebotomy alone).
  • Dietary iron intake in Group B was successfully reduced from 17.6 to 8.2 mg/day.

Conclusions:

  • Phlebotomy alone is insufficient to fully mitigate iron-induced oxidative stress in chronic hepatitis C.
  • A low iron diet provides an additive benefit to phlebotomy in iron reduction therapy.
  • The combination therapy offers superior improvement in liver enzyme levels for chronic hepatitis C patients.
Abstract

More Related Videos

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Related Concept Videos

Lifecycle of Erythrocytes01:22

Lifecycle of Erythrocytes

Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...